Circuit Parties and Patterns of Drug Use in a Subset of Gay Men

Journal of Addictive Diseases

Volumn 22, Issue 4, 2003, Pages 47-60

  Lee, Steven J ^a   Galanter, Marc ^a   Dermatis, Helen ^a   McDowell, David ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Circuit parties; Club drugs; Crystal methamphetamine; Ecstasy; Gamma hydroxybutryrate (GHB); Gay men; Human immunodeficiency virus (HIV); Ketamine; Methylenedioxymethamphetamine (MDMA)

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE DERIVATIVE; COCAINE; KETAMINE; METHAMPHETAMINE;

ADULT; ARTICLE; CAUCASIAN; DRUG USE; EDUCATION; HEALTH BEHAVIOR; HEALTH SURVEY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE DRUG ABUSE; RISK FACTOR; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE;

ADULT; ANNIVERSARIES AND SPECIAL EVENTS; FEMALE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; KETAMINE; MALE; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEW YORK; RISK-TAKING; SEXUAL BEHAVIOR; SODIUM OXYBATE; SUBSTANCE-RELATED DISORDERS;

EID: 0842288233     PISSN: 10550887     EISSN: None     Source Type: Journal    
DOI: 10.1300/J069v22n04_05     Document Type: Article

References (68)

1. Houchins, J. Partying to death: self-destructive behavior in the gay community. Next Magazine. 1998;6:10.
2. Shioya T. Tales of the circuit. San Francisco Weekly. 13 May, 1998, p. 17.
3. Signorile M. Life Outside. New York: Harper Collins, 1997.
4. Winter Circuit. Circuit Noize. 1998:Fall:41-46.
5. Bad Boy Club Montreal Foundation. The History of BBCM. www.bbcm.org/ home.htm. Accessed April 22, 2002.
6. JS Enterprises. http://www.jeffreysanker.com/full_window.html. Accessed 22 April, 2002.
7. Mansergh G, Colfax GN, Marks G, et al. The circuit party men's health survey: findings and implications for gay and bisexual men. Am J Public Health. 2001;91: 953-958.
8. Mattison AM, Ross MW, Wolfson T, et al. Circuit party attendance, club drug use, and unsafe sex in gay men. J Subst Abuse. 2001;13:119-126.
9. Bruni F. Drugs taint an annual round of gay revels. The New York Times. 8 Sept 1998, B1.
10. Substance Abuse and Mental Health Services Administration. Now trends released for drug related emergency department visits. National Clearinghouse for Alcohol and Drug Information. 25 July 2001. http://www.health.org/newsroom/releuses/ 2001/july01/10.htm. Accessed 22 April 2002.
11. Klitzman RL, Pope HG Jr, Hudson JI. MDMA ("Ecstasy") abuse and high-risk sexual behaviors among 169 gay and bisexual men. Am J Psychiatry. 2000;157: 1162-1164.
12. Ramirez A. Gay charity cites drug use in canceling a fund-raiser. The New York Times. 1 Jan 1999, B1.
13. McDowell D, Kleber H. MDMA, its history and pharmacology. Psychiatric Annals. 1994;24:127-130.
14. Jimenez, J. The word on the street. Next Magazine. 1998;6:12-13.
15. Rattray M. Ecstasy: towards an understanding of the biochemical basis of the actions of MDMA. Essays Biochem. 1991;26:77-87.
16. McDowell D. MDMA, ketamine, GHB, and the "club drug" scene. In: Galanter M, Kleber H, ed. Textbook of Substance Abuse Treatment. Washington: American Psychiatric Press, 1999:295-305.
17. Ritz MC, Lamb RJ, Goldberg SR, et al. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237:1219-1223.
18. Jaber M, Jones S, Giros B, et al. The dopamine transporter: a crucial component regulating dopamine transmission. Mov Disord. 1997;12:629-633.
19. Gold MS, Herkov MJ. The pharmacology of cocaine, crack and other stimulants. In: Graham AW, Schultz TK, ed. Principles of Addiction Medicine, Second Edition. Chevy Chase: American Society of Addiction Medicine, 1998:137-146.
20. Galloway GP, Frederick SL, Staggers FE, et al. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction. 1997;92:89-96.
21. Tunnicliff G. Sites of action of gamma-hydroxybutyrate (GHB)-a neuroactive drug with abuse potential. Clin Toxicol. 1997;35:581-590.
22. Andreu V, Mas A, Bruguera M, et al. Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol. 1998;29:394-397.
23. Brauer RB, Heidecke CD, Nathrath W, et al. Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy. Transpl Int. 1997;10:229-233.
24. De Carlis L, De Gasperi A, Slim AO, et al. Liver transplantation for ecstasy-induced fulminant hepatic failure. Transplant Proc. 2001;33:2743-2744.
25. Ellis AJ, Wendon JA, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut. 1996;38:454-458.
26. Garbino J, Henry JA, Mentha G, Romand JA. Ecstasy ingestion and fulminant hepatic failure: liver transplantation to be considered as a last therapeutic option. Vet Hum Toxicol. 2001;43:99-102.
27. Lawler LP, Abraham S, Fishman EK. 3,4-Methylenedioxymethamphetamine (ecstasy)-induced hepatotoxicity: multidetector CT and pathology findings. J Comput Assist Tomogr. 2001;25:649-652.
28. Qasim A, Townend J, Davies MK. Ecstasy induced acute myocardial infarction. Heart. 2001;5:E10.
29. Ajaelo I, Koenig K, Snoey E. Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use. Acad Emerg Med. 1998;5:839-840.
30. Gomez-Balaguer M, Pena H, Morillas C, Hernandez A. Syndrome of inappropriate antidiuretic hormone secretion and "designer drugs" (ecstasy). J Pediatr Endocrinol. 2000;13:437-438.
31. Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gamma-hydroxybutyrate in California. West J Med. 1992;156:380-384.
32. Dyer JE. Gamma-hydroxybytyrate: a health-food product producing coma and seizurelike activity. Am J Emerg Med. 1991;9:321-324.
33. Ingels M, Rangan C, Bellezzo J, Clark RF. Coma and respiratory depression following the ingestion of GHB and its precursors: three cases. J Emerg Med. 2000;19:47-50.
34. Steele MT, Watson WA. Acute poisoning from gamma hydroxybutyrate (GHB). Mo Med. 1995;92:354-357.
35. Bolla KI, McCann UD, Ricaurte GA. Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology. 1998;51:1532-1537.
36. McCann UD, Ridenour A, Shaham Y, Ricuarte GA. Serotonin neurotoxicity after (+/-) 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology. 1994;10:129-138.
37. McCann U, Slate S, Ricaurte G. Adverse reactions with 3,4-methylenedioxy-methamphetamine (MDMA; "Ecstasy"). Drug Saf. 1996;15:107-115.
38. McCann UD, Ricaurte GA, Molliver ME. "Ecstasy" and serotonin neurotoxicity: new findings raise more questions. Arch Gen Psychiatry. 2001;58:907-908.
39. Obrocki J, Buchert R, Vaterlein O, et al. Ecstasy-long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry. 1999;175:186-188.
40. Reneman L, Majoie CB, Habraken JB, den Heeten GJ. Effects of ecstasy (MDMA) on the brain in abstinent users: initial observations with diffusion and perfusion MR imaging. Radiology. 2001;220:611-617.
41. Ricaurte GA, Yuan J, McCann UD. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology. 2000;42:5-10.
42. Bhattachary S, Powell JH. Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or 'ecstasy': evidence for cognitive impairment. Psychol Med. 2001;31:647-658.
43. Buchert R, Obrocki J, Thomasius R, et al. Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET. Nucl Med Commun. 2001;22:889-897.
44. Morgan MJ. Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacologia. 1999;141:30-36.
45. Parrott AC, Lees A, Garnham NJ, et al. Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits. J Psychopharmacol. 1998;12:79-83.
46. Reneman L, Majoie CB, Schmand B, et al. Prefrontal N-acetylaspartate is strongly associated with memory performance in (abstinent) ecstasy users: preliminary report. Biol Psychiatry. 2001;50:550-554.
47. Verkes RJ, Gijsman HJ, Pieters MS, et al. Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacologia. 2001;153:196-202.
48. Zakzanis KK, Young DA. Memory impairment in abstinent MDMA ("Ecstasy") users: a longitudinal investigation. Neurology. 2001;56:966-969.
49. White JM, Ryan CF. Pharmacological properties of ketamine. Drug Alcohol Review. 1996;15:145-155.
50. Kosten TR, Singha AK. Stimulants. In: Galanter M, Kleber H, ed. Textbook of Substance Abuse Treatment. Washington: American Psychiatric Press, 1999:183-193.
51. Rofes E. Dry Bones Breathe: Gay Men Creating Post-AIDS Identities and Cultures. Binghamton: Haworth Press, 1998.
52. Paris D, Ledergerber B, Weber R, et al. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses. 1999;15:1631-1638.
53. Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med. 1999;159:2221-2224.
54. Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet. 1998;352:1751-1752.
55. Connor TK, Kelly JP, Leonard BE. An assessment of the acute effects of the serotonin releasers methylenedioxymethamphetamine, methylenedioxyamphetamine and fenfluramine on immunity in rats. Immunopharmacology. 2000;46:223-245.
56. Connor TJ, McNamara MG, Finn D, et al. Acute 3,4methylenedioxymethamphetamine (MDMA) administration produces a rapid and sustained suppression of immune function in the rat. Immunopharmacology. 1998;38:253-260.
57. Nuñez-Iglesias MJ, Castro-Bolaño C, Losada C, et al. Effects of amphetamine on cell mediated immune response in mice. Life Sci. 1996;58:29-33.
58. Pacifici R, Zuccaro P, Farre M, et al. Effects of repeated doses of MDMA ("ecstasy") on cell-medicated immune response in humans. Life Sci. 2001;69:2931-2941.
59. Pacifici R, Zuccaro P, Farre M, et al. Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. Life Sci. 1999;65:PL309-PL316.
60. Pellegrino T, Bayer BM. In vivo effects of cocaine on immune cell function. J Neuroimmunology. 1998;83:139-147.
61. Freire-Garabal M, Balboa JL, Núñez MJ, et al. Effects of amphetamine on T-cell immune response in mice. Life Sci. 1991;49:PL107-PL112.
62. Bagasra O, Pomerantz RJ. Human immunodeficiency virus type I replication in peripheral blood mononuclear cells in the presence of cocaine. J Infect Dis. 1993;168:1157-1164.
63. Roth MD, Tashkin DP, Choi R, et al. Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. J Infect Dis. 2002;185:701-705.
64. Gleghorn A, Marx R, Vittinghoff E, Katz MH. Association between drug use patterns and HIV risk among homeless, runaway, and street youth in northern California. Drug Alcohol Depend. 1998;51:219-227.
65. Hser YI, Chou CP, Hoffman V, Anglin MD. Cocaine use and high-risk sexual behavior among STD clinic patients. Sex Transm Dis. 1999;26:82-86.
66. Wingood GM, DiClemente RJ. The influence of psychosocial factors, alcohol, drug use on African-American women's high-risk sexual behavior. Am J Prev Med. 1998;15:54-59.
67. Henry J. Kaiser Family Foundation. Youth Knowledge and Attitudes on Sexual Health: A National Survey of Adolescents and Young Adults, Feb 2002.
68. Hoffman W. As critics attack circuit parties, health activists quietly switch tactics. The New York Blade. 14 August 1998, p. 1.